Danielle Gilliam on FDA’s Approval of Wegovy Pill from Novo Nordisk
Danielle Gilliam, Executive Medical Science Liaison Cardiovascular and Renal at Novo Nordisk North America, shared on LinkedIn:
”The FDA’s approval also clears the pill for use to reduce the risk of major cardiovascular events, such as death, heart attack or stroke, in adults with obesity and established cardiovascular disease, according to Novo Nordisk.”
Find more here.
Read the full announcement by Novo Nordisk here.
Novo Nordisk announced that the US Food and Drug Administration has approved the Wegovy pill, a once-daily oral semaglutide 25 mg, for long-term weight reduction and maintenance, as well as for reducing the risk of major adverse cardiovascular events.
The oral formulation is indicated for adults with obesity or overweight who have at least one weight-related comorbidity, and for adults with established heart disease to lower the risk of death, heart attack, or stroke.
In addition, Wegovy injection is approved for chronic weight management in paediatric patients aged 12 years and older.
The injectable form is also approved for the treatment of MASH in adults with moderate to advanced liver fibrosis, excluding those with cirrhosis.
Stay updated with Hemostasis Today.
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?